All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Lova Sun of Massachusetts General Hospital, and colleagues, published results of 16 years of retrospective chart review for outcomes of autologous stem cell transplant (ASCT) in patients over 70 years old. The review was published in the online edition of The Oncologist December 28, 2017.
ASCT is the standard treatment for chemotherapy-sensitive relapsed lymphoma patients. Medical practitioners may be hesitant to offer transplant to older patients due to concerns for higher risk for poor outcomes due to infections, organ toxicities or non-relapse mortality (NRM). The purpose of this review was to observe safety outcomes over an extended period and determine if any clinical factors influence favorable versus poor outcomes in elderly lymphoma patients.
This study demonstrated that elderly patients are still viable candidates for ASCT, with good clinical outcomes and acceptable expected toxicities. Survival status has improved in recent years, which likely reflects improvements in supportive care, toxicity management and infection prophylaxis. The authors recommended that elderly lymphoma patients should be selected based on individual patient characteristics for ASCT and not excluded as candidates based on age alone.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox